Marit Sjo Lorentzen

Direttore operativo presso ARCTICZYMES TECHNOLOGIES ASA

Patrimonio netto: 47 550 $ in data 30/04/2024

56 anni

Health Technology

Consumer Services

Profilo

Marit Sjo Lorentzen is currently the Director at Biotec BetaGlucans AS and the Vice President-Operations at ArcticZymes Technologies ASA. She has an undergraduate degree from the University of Tromso.

Partecipazioni note in società pubbliche

Società	Data	Numero di azioni	Valorizzazione	Data di valutazione
ARCTICZYMES TECHNOLOGIES ASA 0.04%	31/03/2023	20 331 ( 0.04% )	47 550 $	30/04/2024

Posizioni attive di Marit Sjo Lorentzen

Società	Posizione	Inizio
ARCTICZYMES TECHNOLOGIES ASA	Direttore operativo	-
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Direttore/Membro del Consiglio	-

Tutte le posizioni attive di Marit Sjo Lorentzen

Formazione di Marit Sjo Lorentzen

University of Tromso

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Marit Sjo Lorentzen

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
ARCTICZYMES TECHNOLOGIES ASA	Health Technology

Aziende private	1
Biotec BetaGlucans AS Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million.	Health Technology